Molecule
Ixekizumab is an interleukin-17A antagonist indicated for the treatment of patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, among other approved uses. MedsAcross supplies Ixekizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. adults with active psoriatic arthritis. adults with active ankylosing spondylitis. adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
Source: US FDA prescribing information
Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.
Source: US FDA prescribing information
Administer by subcutaneous injection. Adult Plaque Psoriasis. Recommended dosage is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks. Pediatric Plaque Psoriasis. For patients weighing greater than 50 kg, recommended dosage is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. For patients weighing 25-50 kg, recommended dosage is 80 mg at Week 0, followed by 40 mg every 4 weeks. For patients weighing less than 25 kg, recommended dosage is 40 mg at Week 0, followed by 20 mg every 4 weeks. Psoriatic Arthritis. Recommended dosage is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for adult plaque psoriasis.
Source: US FDA prescribing information
TALTZ is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients. Serious hypersensitivity reaction to ixekizumab or to any of the excipients.
Source: US FDA prescribing information
Infections: Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue TALTZ until the infection resolves. Tuberculosis (TB): Evaluate for TB prior to initiating treatment. Hypersensitivity: If a serious allergic reaction occurs, discontinue TALTZ immediately and initiate appropriate therapy. Eczematous Eruptions: In the postmarketing setting, cases of severe eczematous eruptions were reported in patients receiving TALTZ. Treatment may need to be discontinued to resolve the eczematous eruption. Inflammatory Bowel Disease: Crohn's disease and ulcerative colitis, including exacerbations, occurred during clinical trials. Monitor closely when prescribing TALTZ to patients with inflammatory bowel disease (IBD).
Source: US FDA prescribing information
The following adverse drug reactions are discussed in greater detail in other sections of the label: Infections Hypersensitivity Reactions Eczematous Eruptions Inflammatory Bowel Disease Most common (≥1%) adverse reactions associated with TALTZ treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.
Source: US FDA prescribing information
Store refrigerated at 2°C to 8°C (36°F to 46°F). If needed, patients/caregivers may store TALTZ at room temperature up to 30°C (86°F) for up to 5 days in the original carton to protect from light. Once TALTZ has been stored at room temperature, do not return to the refrigerator and discard, if unused, within 5 days. Record the date when TALTZ is first removed from the refrigerator in the spaces provided on the carton. For the 2 or 3 autoinjector pack, remove a single autoinjector at a time leaving the remaining autoinjector(s) in the original carton in the refrigerator. Ensure the unrefrigerated TALTZ is protected from light. Do not freeze. Do not shake.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Ixekizumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Taltz 80 mg/1 mL injectionSubcutaneous Cold chain | Eli Lilly | US FDA | Available on request |
| Taltz 20 mg/0.25 mL injectionSubcutaneous Cold chain | Eli Lilly | US FDA | Available on request |
| Taltz 40 mg/0.5 mL injectionSubcutaneous Cold chain | Eli Lilly | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 3 presentations of Ixekizumab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ixekizumab, including Taltz.
Yes. The US FDA first approved Ixekizumab on 22 March 2016, according to Drugs@FDA.
Yes. Ixekizumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Ixekizumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Ixekizumab is classified under ATC code L04AC13 (Ixekizumab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.